Results 91 to 100 of about 68,651 (161)

Pancreatic Ductal Adenocarcinoma

, 2012
Eric P. Tamm, Jason B. Fleming, Gauri R. Varadhachary   +2 more
openaire   +2 more sources

CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. [PDF]

Cancers (Basel)
Kucukcelebi S, Diepen AEV, Vos-Geelen J, van Eijck CHJ, Montfoort NV, Eijck CWFV.   +5 more
europepmc   +1 more source

Epigenetic Regulators as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma. [PDF]

Cancers (Basel)
Kubiak K, Inkielewicz-Stępniak I.
europepmc   +1 more source

KRAS-driven immune exclusion in pancreatic ductal adenocarcinoma: mechanisms and therapeutic reversal. [PDF]

Oncologist
Kern KA.
europepmc   +1 more source

Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond. [PDF]

Ther Adv Med Oncol
Misirian A, Pai J, Hanna DL.
europepmc   +1 more source

Perioperative Thyroid-Metabolic Changes in Pancreatic Ductal Adenocarcinoma According to Surgical Management. [PDF]

Cancers (Basel)
Grząsiak-Kraj O, Kraj T, Majos A, Wardęszkiewicz A, Szmiel A, Poznański K, Durczyński A, Hogendorf P, Strzelczyk J.   +8 more
europepmc   +1 more source

CT-based vascular invasion in pancreatic ductal adenocarcinoma compared with intraoperative and histological findings. [PDF]

Insights Imaging
Nacul Mora G, Andreou A, Maksoud Z, Becker F, Heitplatz B, Wardelmann E, Strücker B, Katou S, Morgül H, Pascher A, Köhler M, Pöhler GH.   +11 more
europepmc   +1 more source

Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma. [PDF]

Cells
Živić K, Pavlović M, Ostojić M, Galun D, Pavić A, Srdić-Rajić T, Grahovac J.   +6 more
europepmc   +1 more source

MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma. [PDF]

Front Immunol
Xu H, Wang Q, Cao R, Qiu Z, Liu Y, Hu J, Zheng G, Cheng C.   +7 more
europepmc   +1 more source